Tritium labelling of several potent fluorinated antipsychotic drugs at high specific activity

Applied Radiation and Isotopes

Volumn 65, Issue 7, 2007, Pages 827-830

  Ahern, David G ^a   Laseter, Anne G ^a   Filer, Crist N ^a  

^a PERKINELMER INC   (United States)

Author keywords

Antipsychotic; Haloperidol; Trifluoperazine; Tritium; Tritium NMR

Indexed keywords

ALCOHOLS; NITROGEN COMPOUNDS; NUCLEAR MAGNETIC RESONANCE; RADIOACTIVE TRACERS; RADIOACTIVITY; TRITIUM;

ANTIPSYCHOTIC DRUGS; HALOPERIDOL; TRIFLUOPERAZINE;

DRUG PRODUCTS;

HALOPERIDOL; NEUROLEPTIC AGENT; TRIFLUOPERAZINE; TRITIUM;

ARTICLE; DRUG LABELING; DRUG SYNTHESIS; FLUORINATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

ANTIPSYCHOTIC AGENTS; HALOPERIDOL; MAGNETIC RESONANCE SPECTROSCOPY; TRIFLUOPERAZINE; TRITIUM;

EID: 34248191316     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2007.02.008     Document Type: Article

References (15)

1. Bolos J. Current strategies for the development of novel antipsychotic drugs. Mini-Rev. Med. Chem. 3 (2003) 239-251
2. Craig P.N., Nodiff E.A., Lafferty J.L., and Ullyot G.E. New trifluoromethylphenothiazine derivatives. J. Org. Chem. 22 (1957) 709-711
3. Egan J.A., Nugent R.P., and Filer C.N. Colforsin analogues: tritiation and characterization. Appl. Radiat. Isot. 61 (2004) 1269-1272
4. Filer C.N. Isotopic fractionation of organic compounds in chromatography. J. Label. Cpd. Radiopharm. 42 (1999) 169-197
5. Janssen P.A.J., Van de Westeringh C., Jageneau A.H.M., Demoen P.J.A., Hermans B.K.F., Van Daele G.H.P., Schellekens K.H.L., Van der Eycken C.A.M., and Niemegeers C.J.E. Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-4-phenylpiperidino)butyrophenone. I. Synthesis and screening data in mice. J. Med. Pharm. Chem. 1 (1959) 281-297
6. Leonard B.E. Sigma receptors and sigma ligands: background to a pharmacological enigma. Pharmacopsychiatry 37 (2004) S166-S170
7. Mach R.H., Huang Y., Freeman R.A., Wu L., Vangveravong S., and Luedtke R.R. Conformationally-flexible benzamide analogues as dopamime D3 and sigma 2 receptor ligands. Bioorg. Med. Chem. Lett. 14 (2004) 195-202
8. Muccino R.R., and Serico L. Alumina catalyzed tritium exchange of enolizable hydrogens. J. Label. Cpd. Radiopharm. 15 (1978) 523-527
9. Nakashima Y. Receptor occupancy research using PET/SPECT. No No Kagaku 21 (1999) 643-649
10. Natsvlishvilli N., Juravliova E., Dzneladze D., and Mikeladze D. Haloperidol regulates the binding of guanine nucleotides to synaptic membranes through the NMDA receptor. J. Biol. Phys. Chem. 1 (2001) 24-28
11. Procyshyn R.M., Tsai G., and Wasan K.M. The influence of dyslipidemia on the plasma protein and lipoprotein distribution of haloperidol. Eur. Neuropsychopharm. 13 (2003) 33-37
12. 3H] haloperidol uptake in rat brain. Br. J. Pharmacol. 138 (2003) 188-192
13. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin. Ther. Targets 10 (2006) 515-531
14. Silvestre J.S., and Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Findings Exp. Clin. Pharm. 27 (2005) 289-304
15. Zolyomi G. Tritium labelled compounds of high specific activity. III. Trifluoperazine. J. Label. Cpd. Radiopharm. 24 (1987) 833-837